Efficacy and Safety of Furmonertinib in EGFR-Mutant, PD-L1+ Patients With Locally Advanced or Metastatic NSCLC (FUTURE)

Sponsor
Fudan University
Study ID
NCT05255406
Phase
PHASE2
Status
Unknown

Conditions

  • Non-Small-Cell Lung Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Furmonertinib (160mg) — DRUG
    160mg/day orally on a continuous dosing schedule. If subjects suffer from AEs, they can get declined dosage (80mg).

Study Details

The aim of this phase Ⅱ study is to evaluate the efficacy and safety of Furmonertinib in EGFR-Mutant, PD-L1+ Patients With Locally Advanced or Metastatic NSCLC.

Key Dates

Start date
Dec 9, 2021
Status verified
Aug 2022
Primary completion
Dec 31, 2023
Completion
Dec 31, 2024

Study Design

Enrollment
62 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Furmonertinib
    Furmonertinib (160mg)

Primary Outcome Measure

One-year Progression Free Survival Rate [ Time Frame: One year after inclusion ]

Central Contacts

Related Studies